Neuland Laboratories Limited Total Assets
Neuland Laboratories Limited total assets. Based on the latest financial reports, Neuland Laboratories Limited (NEULANDLAB) holds total assets worth Rs29.30 Billion INR (≈ $316.88 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Neuland Laboratories Limited stock valuation for the company's overall valuation and market capitalisation.
Total Assets of Neuland Laboratories Limited (2006–2026)
Total assets of Neuland Laboratories Limited from 2006 to 2026. This chart illustrates how Neuland Laboratories Limited's total assets have evolved over time, based on quarterly financial data. See NEULANDLAB stock price and chart for real-time trading data and today's change.
Neuland Laboratories Limited - Asset Composition Analysis
Neuland Laboratories Limited Total Assets Breakdown (March 2026)
Neuland Laboratories Limited total assets breakdown as of March 2026. Neuland Laboratories Limited's total assets of Rs29.30 Billion consist of 50.6% current assets and 49.4% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 12.1% |
| Accounts Receivable | Rs5.41 Billion | 18.5% |
| Inventory | Rs5.10 Billion | 17.4% |
| Property, Plant & Equipment | Rs0.00 | 0.0% |
| Intangible Assets | Rs62.66 Million | 0.2% |
| Goodwill | Rs2.79 Billion | 9.5% |
Asset Composition Trend (2006–2026)
This chart illustrates how Neuland Laboratories Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital to net assets of Neuland Laboratories Limited to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Neuland Laboratories Limited's current assets represent 50.6% of total assets in 2026, a decrease from 64.7% in 2006.
- Cash Position: Cash and equivalents constituted 12.1% of total assets in 2026, up from 1.3% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 9.0% of total assets, a decrease from 26.0% in 2006.
- Asset Diversification: The largest asset category is accounts receivable at 18.5% of total assets.
Neuland Laboratories Limited Competitors by Total Assets
Key competitors of Neuland Laboratories Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Galderma Group N
SW:GALD
|
Switzerland | CHF12.88 Billion |
|
Enzymatica publ AB
ST:ENZY
|
Sweden | Skr149.24 Million |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥13.98 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.01 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥10.50 Billion |
Neuland Laboratories Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.09 | 2.45 | 1.49 |
| Quick Ratio | 1.37 | 1.62 | 0.82 |
| Cash Ratio | 0.00 | 0.27 | 0.00 |
| Working Capital | Rs7.73 Billion | Rs6.74 Billion | Rs1.81 Billion |
Neuland Laboratories Limited - Advanced Valuation Insights
This section examines the relationship between Neuland Laboratories Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 11.51 |
| Latest Market Cap to Assets Ratio | 0.09 |
| Asset Growth Rate (YoY) | 34.4% |
| Total Assets | Rs29.30 Billion |
| Market Capitalization | $2.73 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Neuland Laboratories Limited's assets below their book value (0.09x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Neuland Laboratories Limited's assets grew by 34.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Neuland Laboratories Limited (2006–2026)
The table below shows the annual total assets of Neuland Laboratories Limited from 2006 to 2026.
| Year | Total Assets | Change |
|---|---|---|
| 2026-03-31 | Rs29.30 Billion ≈ $316.88 Million |
+34.42% |
| 2025-03-31 | Rs21.80 Billion ≈ $235.75 Million |
+18.95% |
| 2024-03-31 | Rs18.33 Billion ≈ $198.18 Million |
+16.00% |
| 2023-03-31 | Rs15.80 Billion ≈ $170.85 Million |
+14.19% |
| 2022-03-31 | Rs13.83 Billion ≈ $149.62 Million |
+4.43% |
| 2021-03-31 | Rs13.25 Billion ≈ $143.27 Million |
+7.62% |
| 2020-03-31 | Rs12.31 Billion ≈ $133.13 Million |
+8.90% |
| 2019-03-31 | Rs11.30 Billion ≈ $122.24 Million |
+5.50% |
| 2018-03-31 | Rs10.71 Billion ≈ $115.87 Million |
+20.98% |
| 2017-03-31 | Rs8.86 Billion ≈ $95.77 Million |
+68.99% |
| 2016-03-31 | Rs5.24 Billion ≈ $56.67 Million |
+2.45% |
| 2015-03-31 | Rs5.12 Billion ≈ $55.32 Million |
+5.80% |
| 2014-03-31 | Rs4.83 Billion ≈ $52.29 Million |
+13.76% |
| 2013-03-31 | Rs4.25 Billion ≈ $45.96 Million |
-0.21% |
| 2012-03-31 | Rs4.26 Billion ≈ $46.06 Million |
-0.02% |
| 2011-03-31 | Rs4.26 Billion ≈ $46.07 Million |
+7.00% |
| 2010-03-31 | Rs3.98 Billion ≈ $43.06 Million |
+6.58% |
| 2009-03-31 | Rs3.74 Billion ≈ $40.40 Million |
+28.24% |
| 2008-03-31 | Rs2.91 Billion ≈ $31.50 Million |
+46.06% |
| 2007-03-31 | Rs1.99 Billion ≈ $21.57 Million |
+35.46% |
| 2006-03-31 | Rs1.47 Billion ≈ $15.92 Million |
-- |
About Neuland Laboratories Limited
Neuland Laboratories Limited engages in the manufacture and sale of active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. It also provides custom manufacturing solutions, as well as peptide synthesis services. Neuland Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.